Degalix 120 mg Injection

Description

Degalix 120mg Degarelix Injection are manufactured by BDR Pharmaceuticals in India and contain 120mg of Degarelix 120mg per injection. Each Vial includes Pack of 1 Vial, making Degalix 120mg Degarelix Injection an effective option for Prostate Cancer . Prescription Required from your healthcare provider to purchase Degarelix 120mg medicine. Indogenmed deals in all type of generic Degarelix 120mg medicine.

Benefits

• Rapidly reduces testosterone levels, which may help slow prostate cancer growth

• Does not cause an initial testosterone surge (flare) seen with some other hormone therapies

• Used as part of androgen deprivation therapy for prostate cancer

• Administered under medical supervision in a clinical setting

• Helps support long-term management of advanced prostate cancer

Indications and Usage

Degalix (degarelix) may be prescribed for:

• Advanced prostate cancer

• Hormone therapy aimed at reducing testosterone levels

• Patients requiring androgen deprivation therapy (ADT) for prostate cancer management

Treatment decisions are based on disease stage, PSA levels, and clinical evaluation.

How it Works

Degarelix works by blocking gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. Normally, GnRH stimulates the release of hormones that lead to testosterone production in the testes. Testosterone can promote the growth of prostate cancer cells.

By directly inhibiting GnRH receptors, degarelix quickly reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to a rapid decrease in testosterone levels, which may help slow the growth and spread of prostate cancer when the medicine is used as prescribed and monitored by a healthcare professional.

Dosage & Administration

• Degalix is administered as a subcutaneous injection, usually in the abdominal region.

• The injection should be given by trained healthcare professionals.

• Treatment typically begins with an initial loading dose, followed by maintenance injections at regular intervals.

• Dosage and treatment schedules are determined by the treating physician based on clinical needs.

• Patients may require regular monitoring of testosterone and PSA levels during therapy.

Side Effects

Common side effects

• Injection site reactions (pain, redness, swelling)

• Hot flashes

• Weight gain

• Fatigue

• Increased liver enzymes

• Sweating

Serious side effects

• Severe allergic reactions

• Heart rhythm problems (QT prolongation)

• Liver function abnormalities

• Bone thinning with long-term use

• Metabolic changes such as increased blood sugar

Patients should seek medical attention if severe symptoms occur.

Warning and Precaution

• Possible heart rhythm changes (QT prolongation)

• Monitor liver function and hormone levels during treatment

• Injection site reactions are common

• Long-term therapy may contribute to bone density loss

• May cause metabolic changes such as increased blood sugar

• Inform healthcare providers about all medications and supplements before starting treatment

Patient Guidance

• Injections should be administered by healthcare professionals

• Attend all scheduled follow-up appointments and monitoring tests

• Report symptoms such as severe injection reactions, chest pain, or irregular heartbeat

• Maintain regular monitoring of PSA levels and testosterone levels

• Inform your doctor about other medications or medical conditions

• Follow your healthcare provider’s advice regarding diet, exercise, and bone health

Clinical Trial & Approvals

Degarelix has been evaluated in clinical trials studying hormone therapy for advanced prostate cancer. Studies demonstrated that degarelix effectively reduces testosterone levels without causing an initial hormone surge. Based on these findings, degarelix has received approvals from regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of advanced prostate cancer.

References

• U.S. Food and Drug Administration (FDA) – Degarelix Prescribing Information
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022201s016lbl.pdf

• European Medicines Agency (EMA) – Degarelix Product Information
  https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon

• National Cancer Institute – Degarelix Drug Information
  https://www.cancer.gov

• Drugs.com – Degarelix Drug Information
  https://www.drugs.com

• ClinicalTrials.gov – Degarelix Clinical Studies
  https://clinicaltrials.gov

Prescription & documentation note

Degalix 120 mg Injection is typically supplied against a valid prescription and administered by healthcare professionals. For international supply requests, patients may need to provide documentation such as a licensed physician’s prescription, medical records, and identification, depending on destination country regulations. MedsMonk can assist with documentation guidance where applicable.